Skip to main content

Table 3 Information of potential targets and signaling pathways

From: Network pharmacology reveals the multiple mechanisms of Xiaochaihu decoction in the treatment of non-alcoholic fatty liver disease

ID Pathway P value Counts
hsa04933 AGE-RAGE signaling pathway in diabetic complications 3.12E-25 24
hsa05160 Hepatitis C 7.08E-18 22
hsa05418 Fluid shear stress and atherosclerosis 1.16E-17 21
hsa05167 Kaposi sarcoma-associated herpesvirus infection 2.70E-17 23
hsa05222 Small cell lung cancer 5.79E-16 17
hsa05162 Measles 2.88E-15 19
hsa04657 IL-17 signaling pathway 1.75E-14 16
hsa05163 Human cytomegalovirus infection 2.20E-14 22
hsa04932 Non-alcoholic fatty liver disease (NAFLD) 1.72E-13 18
hsa05145 Toxoplasmosis 3.04E-13 16
hsa05161 Hepatitis B 7.49E-13 18
hsa05142 Chagas disease (American trypanosomiasis) 1.15E-12 15
hsa05210 Colorectal cancer 1.63E-12 14
hsa05164 Influenza A 1.73E-12 18
hsa05169 Epstein-Barr virus infection 3.02E-12 19
hsa04066 HIF-1 signaling pathway 3.13E-12 15
hsa05212 Pancreatic cancer 5.57E-12 13
hsa04659 Th17 cell differentiation 3.54E-11 14
hsa05215 Prostate cancer 1.38E-10 13
hsa04931 Insulin resistance 5.44E-10 13
\